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Hypoxia is a prominent feature of chronically inﬂamed tissues.
Oxygen-sensing hydroxylases control transcriptional adaptation to
hypoxia through the regulation of hypoxia-inducible factor (HIF) and
nuclear factor κB (NF-κB), both of which can regulate the inﬂamma-
tory response. Furthermore, pharmacologic hydroxylase inhibitors
reduce inﬂammation in multiple animal models. However, the un-
derlying mechanism(s) linking hydroxylase activity to inﬂammatory
signaling remains unclear. IL-1β, a major proinﬂammatory cytokine
that regulates NF-κB, is associated with multiple inﬂammatory pa-
thologies. We demonstrate that a combination of prolyl hydroxylase
1 and factor inhibiting HIF hydroxylase isoforms regulates IL-1β–in-
duced NF-κB at the level of (or downstream of) the tumor necrosis
factor receptor-associated factor 6 complex. Multiple proteins of the
distal IL-1β–signaling pathway are subject to hydroxylation and
form complexes with either prolyl hydroxylase 1 or factor inhibiting
HIF. Thus, we hypothesize that hydroxylases regulate IL-1β signaling
and subsequent inﬂammatory gene expression. Furthermore, hy-
droxylase inhibition represents a unique approach to the inhibition
of IL-1β–dependent inﬂammatory signaling.
oxygen | inﬂammatory disease | OTUB1 | UBC13
Hypoxia occurs when the demand for oxygen necessary tosatisfy metabolic requirements exceeds the vascular supply.
Whereas it is well established that tissue hypoxia is a feature of
a range of physiologic and pathophysiologic states, including
fetal development, exercise, tumor growth, and ischemia, it has
recently become appreciated that hypoxia is also a prominent
feature in inﬂammatory pathologies, including rheumatoid ar-
thritis and inﬂammatory bowel disease (IBD) (1, 2). Further-
more, hypoxia profoundly impacts upon important inﬂammatory
processes, including the regulation of neutrophil survival, mac-
rophage survival and differentiation, T-cell differentiation, and
dendritic cell function (3).
A key mediator of the immunological and inﬂammatory se-
quelae of hypoxia is the hypoxia-inducible factor (HIF). HIF
is suppressed in the presence of oxygen through the activity
of a family of evolutionarily conserved hydroxylases, of which
there are three prolyl hydroxylases (PHD1, PHD2, and PHD3)
and a single asparaginyl hydroxylase termed factor inhibiting
HIF (FIH). PHDs control the degradation of HIF through
proline hydroxylation with a dominant role for PHD2, whereas
FIH-dependent asparagine hydroxylation is involved in ﬁne
tuning HIF activity by regulating interactions with CREB-
binding protein (CBP)/p300 (4). HIF has been identiﬁed as a key
regulator of inﬂammation and immunity (5, 6), although whether
its activation is ultimately pro- or anti-inﬂammatory in vivo is
likely context speciﬁc. However, the net effect of pharmacologic
activation of this pathway through inhibition of hydroxylases in
vivo is anti-inﬂammatory. The complex role of HIF and in-
ﬂammation and its potential as a therapeutic target have been
recently reviewed (1–3, 7).
NF-κB, a key regulator of inﬂammation is another hypoxia-
responsive transcription factor (8). The same hydroxylases that
confer hypoxic sensitivity upon HIF have been reported to be
responsible for the hypoxic sensitivity of NF-κB (9). Whereas
PHDs have been implicated in the regulation of NF-κB, the
functional site(s) of proline hydroxylation in the pathway has yet
to be identiﬁed (9–11). Conversely, FIH-dependent asparagine
hydroxylation sites on a number of key proteins in the NF-κB
pathway have been identiﬁed; however, the functional impact of
this remains unclear (12, 13). Little is known about whether
hydroxylases regulate NF-κB in the stimulated state as occurs
during active inﬂammation. However, the role of hydroxylases in
inﬂammation is evidenced by the profoundly protective effect of
pharmacologic hydroxylase inhibition in models of colitis, ischemia/
reperfusion, infection, and sepsis (14, 15). The mechanism un-
derpinning this anti-inﬂammatory effect of hydroxylase inhibition is
the topic of the current study.
IL-1β is secreted from multiple cell types and is associated
with a range of inﬂammatory, metabolic, and infectious dis-
eases (16). Upon binding of IL-1β to its cognate receptor, a sig-
naling cascade is initiated, which signals via tumor necrosis factor
(TNF) receptor-associated factor 6 (TRAF6) and the IKK com-
plex resulting in the activation of NF-κB, a master regulator of
inﬂammatory gene expression (17, 18). IL-1β plays a key role in
septic shock, rheumatoid arthritis, inﬂammatory bowel disease,
and type II diabetes and is thus a major therapeutic target (16).
Here, we investigated the regulation of IL-1β–induced NF-κB
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activity by hydroxylases with an aim to identifying therapeutic
targets in the control of IL-1β–induced inﬂammation.
Results
Hydroxylase Inhibition Attenuates IL-1β–Induced NF-κB Activity in
Vitro and in Vivo. We have previously shown that hypoxia ele-
vates basal NF-κB activity both in vitro and in vivo (19). In
contrast to the regulation of basal NF-κB activity, in cells stim-
ulated with IL-1β (but not TNFα), hypoxia inhibits stimulated
NF-κB activity (Fig. S1 A and B). Because, hydroxylases are key
oxygen-sensing enzymes in cells, we investigated the impact of
hydroxylase inhibition on IL-1β–induced NF-κB activity in vivo.
IL-1β treatment led to an increase in NF-κB activity in transgenic
NF-κB–luciferase reporter mice in a manner that was signiﬁ-
cantly attenuated in animals that had been pretreated with the
panhydroxylase inhibitor dimethyloxallyl glycine (DMOG) (Fig.
1 A and B). Ex vivo measurement of luciferase activity in tissues
revealed that the majority of IL-1β–induced NF-κB activity was
in the liver and that this was strongly attenuated in mice pre-
treated with DMOG (Fig. S1 C and D).
To gain mechanistic insight, we next investigated the effects of
hydroxylase inhibition on IL-1β–induced NF-κB activity in cul-
tured cells. HeLa cells were exposed to DMOG (which inhibits
both PHDs and FIH) or the PHD-selective inhibitor JNJ-
42041935 (JNJ1935) (Fig. S2) (20) before stimulation with IL-1β.
Consistent with our in vivo experiments, pretreatment of HeLa
cells with DMOG reduced IL-1β–induced NF-κB activity in
a time- and dose-dependent manner and over a range of IL-1β
concentrations (Fig. 1 C and D). However, JNJ1935 was without
effect on IL-1β–induced NF-κB activity, leading us to hypothe-
size that inhibition of both prolyl and asparaginyl hydroxylation
may be required. Supporting this hypothesis, graded hypoxia
caused gradual reduction in IL-1β–induced NF-κB activity with
maximal inhibition occurring at 1% O2. This is consistent with
PHD inhibition at higher oxygen levels and inhibition of both
PHDs and FIH at lower oxygen levels (Fig. 1E) (21).
PHD1 and FIH Regulate IL-1β–Induced NF-κB Activity in a Combina-
torial Manner. Four isoforms of HIF hydroxylases (PHD1, -2, -3,
and FIH) have been described to confer hypoxic sensitivity on
the HIF transcriptional pathway. We developed our investigation
into the relative role of each of these isoforms alone and in
combination in the hydroxylase-dependent regulation of IL-1β–
induced NF-κB. siRNA-mediated RNA interference allowed us
to speciﬁcally and potently inhibit expression of PHD1, PHD2,
PHD3, or FIH either individually or in combination (Fig. S3 A–
F). In a high-throughput screening assay, single knockdowns of
FIH and PHD1 but not PHD2 or PHD3 reduced IL-1β–induced
NF-κB activity (Fig. S3 G–J). Furthermore, in time course
studies, both PHD1 and FIH knockdown signiﬁcantly reduced
IL-1β–induced NF-κB activity (Fig. S3 K and L). Notably how-
ever, the combinatorial knockdown of PHD1 and FIH was at
least additive (Fig. 2A). Conversely, the overexpression of the
combination of FIH and PHD1 (Fig. S4) signiﬁcantly enhanced
IL-1β–induced NF-κB activity (Fig. 2B). These data led us to
hypothesize that it is a combination of inhibiting both PHD1 and
FIH that is primarily responsible for the inhibitory effects of
hydroxylase inhibitors on IL-1β–induced NF-κB activity.
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Fig. 1. Hydroxylase inhibition attenuates IL-1β–induced NF-κB activity in
vivo and in vitro. (A) IL-1β was administered to NF-κB–luciferase reporter
mice for 4 h with or without DMOG pretreatment (8 mg per mouse, 24 h)
and luciferase activity was visualized by in vivo imaging. (B) In vivo NF-κB
activity was quantiﬁed by measurement of photon release from NF-κB–
luciferase reporter mice. (C) Measurement of IL-1β–induced NF-κB–dependent
transcriptional activity by NF-κB Gaussia luciferase reporter assay in cells
treated with DMOG or JNJ1935. (D) Matrix inhibition assay was used to
measure the effect of DMOG on increasing concentrations of IL-1β–induced
NF-κB–dependent transcriptional activity using a NF-κB Gaussia luciferase
reporter assay. Samples were pretreated for 1 h with DMOG before IL-1β
treatment. Samples were collected 10 h after the addition of IL-1β. (E)
Measurement of IL-1β–induced NF-κB activity by NF-κB Gaussia luciferase
reporter assay 8 h following stimulation in cells grown in graded hypoxic
environments. Data are represented as mean + SEM. n = 3–6 throughout;
*P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA followed by Tukey
posttest.
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Fig. 2. IL-1β–induced NF-κB activity and endogenous gene expression is
regulated in a combinatorial manner by PHD1 and FIH. NF-κB Gaussia
luciferase reporter assay was used to determine the impact of (A) combi-
natorial knockdown and (B) combinatorial overexpression of PHD1 and FIH
on IL-1β–induced NF-κB activation. (C) Western blot analysis of whole cell IL-
1β–induced IκBα protein expression in cells where PHD1 and FIH have been
knocked down alone and in combination. (D) Densitometric analysis of IκBα
protein expression 24 h after IL-1β treatment with and without combina-
torial knockdown of PHD1 and FIH. Data are represented as mean + SEM.
AU, arbitrary unit; NS, not signiﬁcant. N = 4 throughout; *P < 0.05, **P <
0.01, ***P < 0.001 for A; by one-way ANOVA for B.
2 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1309718110 Scholz et al.
Combinatorial PHD1 and FIH Knockdown Attenuates IL-1β–Induced
NF-κB–Dependent Gene Expression. We next investigated the im-
pact of combinatorial knockdown of PHD1 and FIH on the ex-
pression of inhibitor of NF-κB α (IκBα) (a known NF-κB target
gene) in response to stimulation with IL-1β. Cells exposed to IL-
1β demonstrated an acute and transient decrease in IκBα ex-
pression, which is associated with the activation of NF-κB, and
which was followed by a rebound expression as a result of
transcriptional up-regulation by NF-κB (22). Simultaneous
knockdown of FIH and PHD1 reduced the recovery of IκBα,
indicating that the combinatorial knockdown of PHD1 and FIH
inhibits IL-1β–induced NF-κB–dependent gene expression (Fig.
2 C and D).
Hydroxylase Inhibition Reduces TRAF6-Dependent NF-κB Activity.We
next investigated possible sites on the IL-1β pathway at which
hydroxylases may regulate NF-κB. First, we investigated whether
proteins upstream of the TRAF6 complex (Fig. S5A) could be
targets for hydroxylation responsible for the regulation of IL-1β–
induced NF-κB signaling. To do this, we bypassed the IL-1β
receptor and associated proteins by activating NF-κB directly
through overexpression of TRAF6 (23). DMOG strongly inhibited
TRAF6-induced NF-κB activity (Fig. 3A), indicating that the
functional hydroxylation occurs at the level of the TRAF6 com-
plex or downstream of it. Importantly, whereas IL-1β and DMOG
increased HIF expression as previously described (24), the abun-
dance of components of the TRAF6 complex were not altered
(Fig. 3B). Investigating the impact of DMOG on the formation of
the functional E2 ubiquitin-conjugating enzyme of TRAF6, we
found that the interaction between UBC13 and UEV1A (the two
components of the E2 complex) overexpressed in HeLa cells was
not affected by treatment with DMOG (Fig. S5B).
PHD1 and FIH Physically Interact with Proteins of the IL-1β Signaling
Pathway. Having demonstrated that hydroxylase inhibitors regu-
late IL-1β–induced NF-κB signaling, we next investigated pos-
sible substrates for hydroxylation in the IL-1β pathway. To do
this, we used an unbiased mass spectrometry-based approach
to identify proteins that coimmunoprecipitate with individual
hydroxylase isoforms. UEV1A and OTU domain-containing
ubiquitin aldehyde-binding protein 1 (OTUB1), two proteins
associated with the TRAF6 complex (18, 25), were found to be
associated with PHD1 and FIH, respectively, but not with PHD2
or PHD3 (Tables 1 and 2 and Dataset S1). UBC13 is described
to be a further, central component of the complex that interacts
with both UEV1A and OTUB1 (26). To investigate this in our
system, a pulldown of UBC13 was performed. Consistent with
previous reports, we found that UBC13 interacted with both
UEV1A and OTUB1 (Table 3). These data indicate that a
complex containing UBC13, UEV1A, OTUB1, PHD1, and FIH
exists in the IL-1β–signaling pathway.
Downstream of the TRAF6 complex, we found that IκBβ, an
ankyrin-repeat domain (ARD)-containing protein, was associ-
ated with FIH. This is consistent with previous reports that
ARD-containing proteins (including other IκB family members)
are substrates for hydroxylation by FIH (12). We further found
that interaction between FIH and OTUB1, IκBβ and previously
identiﬁed substrates, was promoted in cells treated with DMOG
(Fig. S6 and Dataset S1). As UEV1A is cytosolic and PHD1 has
previously been described as predominantly nuclear (27), we
investigated the cellular distribution of PHD1. We found that
endogenous PHD1 is expressed in both nuclear and cytosolic
compartments in the HeLa cell culture model used here (Fig.
S3M). In summary, several proteins of the IL-1β–signaling
pathway form complexes with either PHD1 or FIH.
Hydroxylation of Proteins in the IL-1β–Signaling Pathway. We next
investigated whether proteins associated with IL-1β signaling
were possible substrates for hydroxylation. For the unbiased
identiﬁcation of hydroxylated proteins of the IL-1β pathway, we
searched a large-scale qualitative dataset (28) downloaded from
the Trance repository against a human database including met,
pro, trp, tyr, asp, asn, and his oxidations as variable modiﬁcations
(Table S1 and Dataset S1) for proteins included in the IL-1β
pathway (18). MS/MS analysis of this HeLa cell proteome
demonstrated that UEV1A (shown to coimmunoprecipitate with
PHD1) (Table 1) was hydroxylated on two adjacent proline
residues (proline 153 and 154 in UEV1A isoform 1). These
proline residues are conserved over ﬁve different UEV1A iso-
forms (Fig. 4 A, D, and E and Fig. S7). Furthermore, UBC13, the
protein forming the functional E2-conjugating enzyme with
UEV1A, was also shown to be hydroxylated on two different
proline residues (Table S1), although no interaction with a PHD
had been identiﬁed. OTUB1 (which was found to interact with
FIH; Table 2) showed ﬁve hydroxylations on amino acid residues
identiﬁed to be speciﬁcally targeted by FIH (asn, asp, and his)
(Table S1) (29, 30). Additionally, we found evidence for prolyl
hydroxylation of OTUB1 in this dataset, although, similar to
UBC13, no direct interaction with a PHD was detected (Table
S1). However, UBC13 interacts strongly with UEV1A (Table 3)
(25) and UEV1A interacts with PHD1 (Table 1). Similarly, OTUB1
forms a complex with UBC13 and UEV1A (Table 3) (26, 31). The
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Fig. 3. Hydroxylase inhibition leads to a reduction of TRAF6-induced NF-κB
activity. (A) NF-κB Gaussia luciferase reporter assay in HeLa cells demon-
strates that NF-κB activity induced by overexpressing TRAF6 is inhibited by
addition of DMOG 6 h after transfection with TRAF6 plasmid. (B) Expression
levels of components of the TRAF6 complex in HeLa cells treated with DMOG
and IL-1β. Data are represented as mean + SEM. AU, arbitrary unit. N = 4
throughout; *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA fol-
lowed by Tukey posttest.
Table 1. Coimmunoprecipitation of components of the IL-1β
signaling pathway with PHD1, -2, and -3
Protein groups
Interacting
proteins
Immunoprecipitation (IP)
PHD1 PHD2 PHD3
Proteins of the
HIF pathway
PHD1 + + +
PHD2 + + +
PHD3 − + +
FIH − − −
HIF-1α + + +
ARNT + + +
Other known
interactors
HSP90 + + +
FKBP38 − + +
Proteins of the
IL-1β pathway
UBC13 − − −
UEV1A + − −
OTUB1 − − −
IκBβ − − −
PHD1, -2, and -3 were immunoprecipitated and the coprecipitants were
analyzed using mass spectrometry. Previously described hydroxylase targets/
interactors served as controls demonstrating effective coimmunoprecipita-
tion. Several different isoforms of HSP90 were found, which were combined
in this table as “HSP90.” For further information see Dataset S1.
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potential spatial proximity of both UBC13 as well as OTUB1 to
PHD1 could therefore explain the observed prolyl hydroxylations.
IκBβ, which, as well as OTUB1, speciﬁcally coimmunoprecipitated
with FIH, was found to be hydroxylated on one aspartate residue
(Table S1).
In addition to those listed above, a number of other proteins
involved in the IL-1β pathway were also found to be hydroxylated
(Table S1).
FLAG-UBC13 pulldown followed by mass-spectrometry–
based analysis conﬁrmed hydroxylations on proline 19 and 21
(Table S1). Furthermore, the analysis identiﬁed multiple sites for
hydroxylation on UBC13, including proline 59 (Fig. 4B). MS/MS
analysis of immunoprecipitated FLAG-HA-OTUB1 conﬁrmed
asparaginyl hydroxylation on N22 in isoform 1 (Otubain-1) (Fig.
4C and Table S1). In addition, we identiﬁed a hydroxylation of
Y26, which is likely to be a nonenzymatic oxidation (Fig. 4C).
Overall, we have demonstrated that PHD1 and FIH play an
important role in modulating IL-1β–induced NF-κB activity. A
number of proteins in the IL-1β–signaling pathway were found to
be associated with hydroxylases. Furthermore, peptides from
these (and other) IL-1β–signaling proteins are found in the hy-
droxylated state. Importantly, although demonstration of asso-
ciation with hydroxylases and the detection of hydroxylated
peptides indicate potential sites of action within this pathway,
they do not deﬁnitively prove that enzymatic hydroxylation has
taken place. Indeed, it is likely that nonenzymatic oxidation of
proteins also occurs. Future studies will be aimed at deciphering
spurious oxidations from enzymatic hydroxylations and identify-
ing which hydroxylation(s) is functionally associated with altered
IL-1β–induced NF-κB activity. Based on this data, we propose
that hydroxylation is a key posttranslational modiﬁcation in the
IL-1β pathway. This may have important implications for the use
of hydroxylase inhibitors in a number of inﬂammatory disorders.
Discussion
Hypoxia is a microenvironmental feature in chronically inﬂamed
tissues due to increased metabolic activity and disrupted perfu-
sion leading to increased oxygen demand and decreased oxygen
supply at the inﬂamed site (1). Furthermore, hypoxia-sensitive
pathways such as HIF and NF-κB, which are under the control of
oxygen-sensing hydroxylases, drive proinﬂammatory responses
in macrophages, T cells, dendritic cells, and neutrophils (1–3).
Based on these observations, it would be predicted that phar-
macologic hydroxylase inhibition in vivo would promote inﬂam-
mation. However, a number of recent studies have somewhat
paradoxically demonstrated a profoundly anti-inﬂammatory ef-
fect of hydroxylase inhibition in multiple models of acute and
chronic inﬂammation (10, 11, 15, 32). In the current study, we
investigated the underlying mechanism(s) of anti-inﬂammatory
action of hydroxylase inhibition with an aim to develop our un-
derstanding of the role of hydroxylases in regulating inﬂam-
matory signaling pathways and the potential for hydroxylase
inhibitors as anti-inﬂammatory therapeutics. In contrast to its
effect on basal NF-κB activity, we found that hydroxylase in-
hibition strongly reduced IL-1β–induced NF-κB activity in a
manner that was dependent upon the combinatorial blockade of
both PHD1 and FIH. This is consistent with data demonstrating
activation of basal NF-κB but inhibition of lipopolysaccharide
(LPS)-induced NF-κB in models of sepsis (15). The regulation of
a hypoxia-sensitive pathway by combinatorial activity of a prolyl
hydroxylase together with FIH has been previously reported in
HIF signaling where inhibition of PHD2 and FIH leads to opti-
mal HIF-dependent transcriptional activity (4). We describe
a comparable combinatorial role for a prolyl hydroxylase and an
asparaginyl hydroxylase (in this case PHD1 and FIH) conferring
optimal oxygen sensitivity upon the IL-1β–signaling pathway.
The mechanism underpinning the beneﬁcial impact of hy-
droxylase inhibition on complex inﬂammatory pathways in vivo
remains incompletely understood (11, 15, 32). A role for IL-1β in
the pathogenesis of IBD has been implicated as it is increased in
the diseased tissue and ampliﬁes NF-κB activity, leading to an
increase of the secretion of inﬂammatory mediators, the rec-
ruitment of inﬂammatory cells, and the secretion of enzymes
such as matrix metalloproteinases (33, 34). Therefore, the down-
regulation of IL-1β–induced NF-κB activity reported likely plays
a role in the beneﬁcial effects of hydroxylase inhibitors in models
of IBD (14, 35).
Previous reports have demonstrated that basal and TNFα-
induced NF-κB activity, which is TRAF6 independent, is increased
with hydroxylase inhibition (11, 32). Furthermore, the non-
canonical NF-κB–signaling pathway, which is also TRAF6 in-
dependent, is unaffected by hydroxylase inhibition (36). However,
LPS-induced NF-κB activity, which is TRAF6 dependent, is
down-regulated (15, 37). We found that similar to LPS, IL-1β–
induced NF-κB activity is down-regulated by hydroxylase in-
hibition. Additionally, TRAF6-induced NF-κB activity was also
down-regulated in the presence of DMOG. Therefore, it appears
that the effects of hydroxylase inhibition on NF-κB signaling is
dependent upon the stimulus used. Overall these data indicate
that the effect of hydroxylase inhibition might be a general effect
for pathways using TRAF6 as a major part of their signaling
cascade.
Table 2. Coimmunoprecipitation of components of the IL-1β
signaling pathway with FIH
Protein groups
Interacting
proteins IP FIH
Proteins of the HIF pathway PHD1 −
PHD2 +
PHD3 −
FIH +
HIF-1α +
ARNT +
Other known interactors Tankyrase-1 +
Tankyrase-2 +
Notch2 +
RIPK4 +
Proteins of the IL-1β pathway UBC13 −
UEV1A −
OTUB1 +
IκBβ +
FIH was immunoprecipitated and the coprecipitants were analyzed using
mass spectrometry. Previously described hydroxylase targets/interactors
served as controls, demonstrating effective coimmunoprecipitation. For further
information, see Dataset S1.
Table 3. Coimmunoprecipitation of components of the IL-1β
signaling pathway with UBC13
Protein groups
Interacting
proteins IP UBC13
Proteins of the HIF pathway PHD1 −
PHD2 −
PHD3 −
FIH −
HIF-1α −
ARNT −
Other known interactors STUB1 +
UEV2 +
Proteins of the IL-1β pathway UBC13 +
UEV1A +
OTUB1 +
IκBβ −
UBC13 was immunoprecipitated and the coprecipitants were analyzed
using mass spectrometry. Previously described interactors served as controls,
demonstrating effective coimmunoprecipitation. For further information,
see Dataset S1.
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We addressed the identiﬁcation of putative functional hy-
droxylation sites in the IL-1β pathway, which may account for the
effects of hydroxylases on IL-1β signaling. Using immunopre-
cipitation (IP) combined with mass spectrometric analysis, we
identify UEV1A and OTUB1 as being associated with PHD1
and FIH, respectively, leading us to hypothesize that these may
be sites of functional hydroxylation. Furthermore, we found that
UEV1A and OTUB1 are also associated with UBC13, leading us
to the hypothesis that PHD1, FIH, UEV1A, OTUB1, and
UBC13 are part of one multiprotein complex in the IL-1β
pathway. Investigating whether UEV1A is indeed a target for
PHD1, we showed that hydroxylation occurred on two different
proline residues with UBC13 and OTUB1 also being prolyl hy-
droxylated. Additionally, we also demonstrated that OTUB1 was
hydroxylated on residues that are speciﬁc for FIH-dependent
hydroxylation (N, D, and H) (29, 30). UEV1A and UBC13 to-
gether form the functional E2 ubiquitin-conjugating enzyme for
TRAF6, whereas OTUB1 was reported to negatively regulate
UEV1A-UBC13 function (25, 26). Furthermore, it has pre-
viously been reported that this complex signals through the
TRAF6 ubiquitin ligase activity.
Downstream of the TRAF6 complex, we found IκBβ to interact
with FIH and to be hydroxylated on an aspartate residue. More-
over, we showed that several proteins of the IL-1β–signaling
pathway downstream of the TRAF6 complex are hydroxylated.
Overall, these results demonstrate that hydroxylation occurs on
multiple proteins in the IL-1β–signaling pathway and PHD1 and
FIH are the main hydroxylase isoforms that regulate IL-1β–induced
NF-κB activity.
The inhibition of IL-1β–induced NF-κB represents a mecha-
nism by which hydroxylase inhibitors are anti-inﬂammatory in
multiple models of IL-1β–driven inﬂammation. However, it
is likely that other mechanisms also contribute to the protective
effects of these drugs in vivo, such as expression of HIF-dependent
epithelial barrier protective genes or hydroxylase-dependent reg-
ulation of intestinal epithelial cell death by apoptosis in inﬂam-
matory bowel disease (1). Further general mechanisms implicated
in the anti-inﬂammatory activity of hydroxylase inhibitors, which
may complement the inhibition of IL-1β signaling include the
regulation of regulatory T-cell abundance (via FoxP3) and the
promotion of adenosine signaling (38, 39).
In summary, pharmacologic hydroxylase inhibition represents
a possible approach to anti-inﬂammatory therapy. In the current
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Fig. 4. Hydroxylation of UEV1A, UBC13, and OTUB1. Tandem mass spectrometric analysis shows hydroxylation of (A) UEV1A on two proline residues (data
were obtained from searching a large-scale qualitative dataset downloaded from the Trance repository), (B) one proline residue in UBC13 in a FLAG-UBC13
immunoprecipitation, and (C) one asparaginyl hydroxylation in OTUB1 in a FLAG-HA-OTUB1 immunoprecipitation. (D) The hydroxylated proline residues of
UEV1A identiﬁed in the large-scale qualitative dataset from the Trance repository are conserved over ﬁve isoforms (here shown as alignment using ClustalW2,
www.ebi.ac.uk/Tools/msa/clustalw2). (E) Position of hydroxylated residues within the different proteins and their isoforms. AA residue (OH), hydroxylated
amino acid residue.
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paper, we provide evidence that a key aspect of the mechanism
of anti-inﬂammatory action of hydroxylase inhibition is via sup-
pression of IL-1β–induced NF-κB–dependent gene expression.
Developing our understanding of the cross-talk, which exists
between oxygen-sensing and inﬂammatory pathways will promote
our understanding of how the microenvironment contributes to
the development of inﬂammation and allow the development of
unique approaches to its control.
Materials and Methods
Cell Culture and Plasmids. Unless otherwise indicated, HeLa cells were used for
cell culture experiments under standard conditions.
The plasmids coding for FLAG-UBC13 and FLAG-HA-OTUB1 were obtained
from Addgene [FLAG-UBC13: plasmid 12460 (40) and FLAG-HA-OTUB1:
plasmid 22551 (41)].
Mass Spectrometric Analysis of Hydroxylated Proteins. We identiﬁed the
UEV1A hydroxylation by searching a large-scale qualitative dataset (28)
downloaded from the Trance repository against a human database in-
cluding met, pro, trp, tyr, asp, asn, and his oxidations as possible mod-
iﬁcations. These data originated from HeLa cells that were grown in
normoxic conditions and lysed and proteins were digested with LysC, trypsin,
or GluC. Higher-energy collisional dissociation (HCD) MS/MS Spectra were
searched with the MaxQuant versions 1.2 and 1.3.
UBC13 and OTUB1 hydroxylations were detected in immunoprecipitated
FLAG-UBC13 or FLAG-HA-OTUB1 samples using a Q-Exactive mass spec-
trometer (Thermo Scientiﬁc) and searchingwith theMaxQuantwithmet, pro,
trp, tyr, asp, asn, and his oxidations as possible modiﬁcations. For the
identiﬁcation of isoform-speciﬁc hydroxylations, peptide sequences con-
taining the hydroxylated amino acid were cross-checked with the Uniprot
database (www.uniprot.org). All other Materials and Methods are described
in SI Materials and Methods.
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